Back to Search
Start Over
Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis.
- Source :
-
Circulation research [Circ Res] 2020 Sep 11; Vol. 127 (7), pp. 877-892. Date of Electronic Publication: 2020 Jun 22. - Publication Year :
- 2020
-
Abstract
- Rationale: Treatment efficacy for diabetes mellitus is largely determined by assessment of HbA1c (glycated hemoglobin A1c) levels, which poorly reflects direct glucose variation. People with prediabetes and diabetes mellitus spend >50% of their time outside the optimal glucose range. These glucose variations, termed transient intermittent hyperglycemia (TIH), appear to be an independent risk factor for cardiovascular disease, but the pathological basis for this association is unclear.<br />Objective: To determine whether TIH per se promotes myelopoiesis to produce more monocytes and consequently adversely affects atherosclerosis.<br />Methods and Results: To create a mouse model of TIH, we administered 4 bolus doses of glucose at 2-hour intervals intraperitoneally once to WT (wild type) or once weekly to atherosclerotic prone mice. TIH accelerated atherogenesis without an increase in plasma cholesterol, seen in traditional models of diabetes mellitus. TIH promoted myelopoiesis in the bone marrow, resulting in increased circulating monocytes, particularly the inflammatory Ly6-C <superscript>hi</superscript> subset, and neutrophils. Hematopoietic-restricted deletion of S100a9 , S100a8 , or its cognate receptor Rage prevented monocytosis. Mechanistically, glucose uptake via GLUT (glucose transporter)-1 and enhanced glycolysis in neutrophils promoted the production of S100A8/A9. Myeloid-restricted deletion of Slc2a1 (GLUT-1) or pharmacological inhibition of S100A8/A9 reduced TIH-induced myelopoiesis and atherosclerosis.<br />Conclusions: Together, these data provide a mechanism as to how TIH, prevalent in people with impaired glucose metabolism, contributes to cardiovascular disease. These findings provide a rationale for continual glucose control in these patients and may also suggest that strategies aimed at targeting the S100A8/A9-RAGE (receptor for advanced glycation end products) axis could represent a viable approach to protect the vulnerable blood vessels in diabetes mellitus. Graphic Abstract: A graphic abstract is available for this article.
- Subjects :
- Animals
Atherosclerosis genetics
Atherosclerosis metabolism
Atherosclerosis pathology
Biomarkers blood
Calgranulin A genetics
Calgranulin A metabolism
Calgranulin B genetics
Calgranulin B metabolism
Diet, High-Fat
Disease Models, Animal
Glucose Transporter Type 1 genetics
Glucose Transporter Type 1 metabolism
Glycolysis
Hyperglycemia blood
Macrophages metabolism
Macrophages pathology
Male
Mice, Inbred C57BL
Mice, Knockout, ApoE
Monocytes pathology
Neutrophils pathology
Plaque, Atherosclerotic
Receptor for Advanced Glycation End Products genetics
Receptor for Advanced Glycation End Products metabolism
Signal Transduction
Atherosclerosis etiology
Blood Glucose metabolism
Hyperglycemia complications
Monocytes metabolism
Myelopoiesis
Neutrophils metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4571
- Volume :
- 127
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Circulation research
- Publication Type :
- Academic Journal
- Accession number :
- 32564710
- Full Text :
- https://doi.org/10.1161/CIRCRESAHA.120.316653